Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24132679 | 0.87 | — | — | |
| SCHEMBL12553815 | 0.87 | IDH1 (0.37) | — | |
| SCHEMBL2625520 | 0.87 | CDK2 (0.44) | HSD17B10CDK2 | |
| SCHEMBL22259380 | 0.87 | IDH1 (0.34) | — | |
| SCHEMBL18532051 | 0.83 | HMGCR (0.38) | — | |
| SCHEMBL21719228 | 0.82 | — | — | |
| SCHEMBL21718497 | 0.82 | — | — | |
| SCHEMBL2739653 | 0.82 | CDK2 (0.44) | HSD17B10CDK2 | |
| SCHEMBL13094524 | 0.82 | — | — | |
| SCHEMBL9883964 | 0.78 | CYP11B2 (0.37) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017742-B | Preparation method of oligomeric isobutene for synthesizing squalane | 万华化学集团股份有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230348640-A1 | Propylene Copolymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348634-A1 | Propylene Polymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348634-A1 | Propylene Polymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090118311-A1 | DHFR Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-07 | — | — | US | disclosed |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | HSD17B10 3465/4885CDK2 3020/4885 |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | HSD17B10 1093/4885CDK2 227/4885 |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | MAPK1, MAPK3, CNKSR1 | HSD17B10 478/4885CDK2 218/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | HSD17B10 2685/4885CDK2 9/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | HSD17B10 3486/4885CDK2 42/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | HSD17B10 2241/4885CDK2 500/4885 |
| US-20090118311-A1 | DHFR Enzyme Inhibitors | DHFR, MTHFD1, ALDH7A1 | HSD17B10 64/4885CDK2 389/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | HSD17B10 3688/4885CDK2 336/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | HSD17B10 2726/4885CDK2 68/4885 |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | TUBB6, MAN2B1, TUBB1 | HSD17B10 2328/4885CDK2 2698/4885 |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | TUBB6, TUBB1, TUBA1C | HSD17B10 2130/4885CDK2 3116/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | HSD17B10 2831/4885CDK2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.